ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Position Increased by William Blair Investment Management LLC

William Blair Investment Management LLC increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 485,268 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,440 shares during the period. William Blair Investment Management LLC owned about 2.31% of ANI Pharmaceuticals worth $26,826,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp raised its holdings in shares of ANI Pharmaceuticals by 9.1% during the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after acquiring an additional 58,698 shares in the last quarter. Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 16.4% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock worth $34,525,000 after acquiring an additional 88,100 shares in the last quarter. Pacer Advisors Inc. raised its holdings in shares of ANI Pharmaceuticals by 23,259.8% during the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after acquiring an additional 565,910 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after acquiring an additional 340,854 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of ANI Pharmaceuticals by 4.2% during the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after acquiring an additional 17,314 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares of the company’s stock, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,200 shares of company stock valued at $191,776. 12.70% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have commented on ANIP shares. HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 14th. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 target price on the stock. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 14th. They set a “buy” rating and a $80.00 target price on the stock. Finally, Guggenheim increased their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $79.75.

ANI Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:ANIP opened at $64.22 on Wednesday. The company has a market cap of $1.40 billion, a P/E ratio of -116.76 and a beta of 0.63. The stock’s 50-day moving average is $58.79 and its 200-day moving average is $58.07. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.